Study of Lenalidomide as a Treatment for Neuropathy Associated With Monoclonal Gammopathy of Undetermined Significance

PHASE2TerminatedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

April 30, 2008

Primary Completion Date

May 19, 2011

Study Completion Date

May 19, 2011

Conditions

NeuropathyNonmalignant Monoclonal Gammopathy of Undetermined Significance (MGUS)

Interventions

DRUG

Lenalidomide

Subjects will receive lenalidomide 25 mg per day for days 1-21 followed by 7 days rest (28-day cycle) for 12 cycles.

Trial Locations (1)

Dartmouth-Hitchcock Medical Center, Lebanon